HIV

Question 1

MOA of NRTI

Answer 1

competitively inhibit reverse transcritpase, leading to viral DNA chain termination

Question 2

class ADR of NRTI

Answer 2

lactic acidosis, hepatic steastosis, lipodystrophy

Question 3

unique ADR of zidovuldine

Answer 3

bone marrow suppression

Question 4

unique ADR of didanosine

Answer 4

pancreatitis

Question 5

nucleotide

Answer 5

tenofovir

Question 6

unique ADR of tenofovir

Answer 6

fanconi syndrome

Question 7

MOA of NNRTIs

Answer 7

direct, non-nucleoside inhibition of RT

Question 8

class ADR of NNRTI

Answer 8

rash (can progress to SJS)

Question 9

can cause w/d in patients taking methadone

Answer 9

nevirapine

Question 10

can cause neuropsych reaction

Answer 10

efavirenz

Question 11

can cause hyperlipidemia

Answer 11

etravirine

Question 12

MOA of PI

Answer 12

prevent formation of functional viral protein

Question 13

class ADR of PI

Answer 13

hyperglycemia, insulin resistance, hyperlipidemia, CAD, fat accumulation and hepatotoxicity

Question 14

PIs effects influenced by (3)

Answer 14

3A4 inducers, H2 blockers, PPIs

Question 15

PI that is only used for boosting other PIs

Answer 15

ritonavir

Question 16

PI that can cause nephrolithiasis

Answer 16

indinavir

Question 17

PI that can increase bilirubin

Answer 17

atazanavir

Question 18

fusion inhibitor

Answer 18

enfuvirtide

Question 19

entry inhibitor

Answer 19

maraviroc

Question 20

maraviroc MOA

Answer 20

CCR5 antagonist

Question 21

raltegravir MOA

Answer 21

integrase inhibitor

Question 22

recommended for use in pregnancy

Answer 22

lopinavir/ritonavir + zidovudine + lamivudine

Question 23

given to infant for first 6 weeks

Answer 23

zidovudine

Question 24

teratogenic HIV med

Answer 24

efavirenz

Question 25

PreP

Answer 25

emtricitabine and tenofovir

Question 26

PEP- when to start, how long to take

Answer 26

start within 72 hours

take for 4 weeks